<DOC>
	<DOCNO>NCT00127530</DOCNO>
	<brief_summary>To assess safety efficacy 10 milligram ( mg ) twice day ( b.i.d . ) Fampridine-SR patient diagnosed multiple sclerosis ( MS ) , double-blind , placebo-controlled , parallel group study .</brief_summary>
	<brief_title>Study Oral Fampridine-SR Multiple Sclerosis</brief_title>
	<detailed_description>Multiple sclerosis ( MS ) disorder body 's immune system affect central nervous system ( CNS ) . Normally , nerve fiber carry electrical impulse spinal cord , provide communication brain arm legs . In people MS , fatty sheath surround insulate nerve fiber ( call `` myelin '' ) deteriorate , cause nerve impulse slow stopped . As result , patient MS may experience period muscle weakness symptom numbness , loss vision , loss coordination , paralysis , spasticity , mental physical fatigue decrease ability think and/or remember . These period illness may come ( exacerbation ) go ( remission ) . Fampridine-SR experimental drug report possibly improve muscle strength walk ability people MS . This study evaluate effect possible risk take Fampridine-SR subject MS .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>4-Aminopyridine</mesh_term>
	<criteria>Have confirm diagnosis multiple sclerosis Are able walk without assistive device Pregnancy , breastfeed female childbearing potential use adequate birth control Participating investigational drug trial A medical history clinical finding preclude entry study A medication history precludes entry study Previously treat 4aminopyridine ( 4AP )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Walking Ability</keyword>
</DOC>